NCT01029730 - Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

October 31, 2014

Study Completion Date

July 31, 2016

Conditions

Lymphoma

Interventions

DRUG

Bendamustine

Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles

DRUG

Bortezomib

Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles

DRUG

Rituximab

Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1

Trial Locations (20)

20817

Center for Cancer and Blood Disorders, Bethesda

National Capital Clinical Research Consortium, Bethesda

26003

Schiffler Cancer Center, Wheeling

30501

Northeast Georgia Medical Center, Gainesville

33308

Holy Cross Hospital, Fort Lauderdale

33916

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

37404

Chattanooga Oncology Hematology Associates, Chattanooga

40207

Baptist Hospital East, Louisville

45242

Oncology Hematology Care, Cincinnati

47802

Providence Medical Group, Terre Haute

49503

Grand Rapids Clinical Oncology Program, Grand Rapids

60076

Hematology Oncology of the North Shore, Skokie

63017

St. Louis Cancer Care, Chesterfield

70806

Hematology Oncology Clinic, LLP, Baton Rouge

72401

NEA Baptist Clinic, Jonesboro

73505

Cancer Centers of Southwest Oklahoma, Lawton

76104

The Center for Cancer and Blood Disorders, Fort Worth

03801

Portsmouth Regional Hospital, Portsmouth

07960

Hematology-Oncology Associates of Northern NJ, Morristown